Mesothelioma

Brenda, who lived in Mytchett when Alan worked for EFCO but later moved to Abingdon near Oxford, said: “The cancer affected him very quickly and after his death there was an autopsy.

An inquest in July 2004 confirmed that he died from an industrial disease.

“He did say to me when he was ill that someone should pay for this, for taking him away from us.

“We are not money-orientated people and we never have been but that was what he said.” Brenda and her family sought the advice of a solicitor in October 2003 following her husband’s death.

Before his death, Alan signed a statement saying he believed his exposure to asbestos had occurred at EFCO.

But further evidence is required.

Brenda added: “I was 55 when he died and we thought we would go on to retire and have a life together.

He was unable to walk his daughter, Andrea, up the aisle as she married three weeks after he died.

I know he was very upset about that and after family discussions I walked her down the aisle on her wedding day.

“He could distinctly remember EFCO and there must be someone who remembers him from back then.

We need to contact someone who can back up Alan’s story — It’s just a life cut short.” EFCO has been bought by another company and the operation that Mr Plows worked for no longer exists.

It is not related to any other firm of the same or similar name in the area.

Peter Lodge at BPE Solicitors rep...

A single dose of the modified SS1P resulted in complete regression of the mouse tumors - the first time that such an effect has been observed.The research is described in the current issue of the bi-monthly journal Bioconjugate Chemistry.

Copyright � 2007 by United Press International Printer friendly version What is the aim of the book of Abkhazian history?

Propaganda against Georgia Desire of self-affirmation Independence of Abkhazia Another canned dog food is recalled Mediterranean diet may help asthma Climate change to hit poorest hardest Russia bans W.

Va.

poultry for bird flu Researchers find genes tied to obesity Study lauds India's biotech industry Protein is new cancer treatment target Aspirin study may advance cancer treatment Study: drugs may stop breast cancer spread Study backs dinosaur-bird relation theory About Us Advertising � 2003-2007 Imedi Television and Radio Broadcasting Corporation.

All rights...

In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single- agent and in combination chemotherapy regimens.

In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials.

About CuraGen CuraGen Corporation (Nasdaq: CRGN) is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody- drug conjugate and small molecule therapeutics.

By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of patients with cancer and inflammatory diseases.

CuraGen is focused on bringing velafermin, belinostat and CR011-vcMMAE through clinical development, and maintains a portfolio of earlier-stage compounds that have the potential to treat cancer and inflammatory diseases.

CuraGen Corporation is headquartered in Branfo...